Advertisement


Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy

2024 ASCO Annual Meeting

Advertisement

Yasmin H. Karimi, MD, of the University of Michigan Comprehensive Cancer Center, discusses 2.5-year follow-up data on epcoritamab monotherapy for patients with relapsed or refractory large B-cell lymphoma. The subcutaneous regimen continues to demonstrate durable responses (Abstract 7039).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
EPCORE NHL-1 was a phase 2 trial evaluating Epcoritamab, a CD20, CD3-bispecific antibody in the treatment of relapsed refractory large cell lymphoma in the second line and beyond setting. In this poster, we presented longer term follow-up results, MRD results, as well as results from the optimization cohort. In the study, patients with relapsed refractory disease were enrolled and treated with Epcoritamab step-up dosing with full dose given on cycle 1, day 15. In the optimization cohort, the dosing schema remained the same. However, CRS prophylaxis was 15 milligrams, dexamethasone, and 500 milliliters of hydration. In the optimization cohort, hospitalization for CRS monitoring after full dose treatment was not required. 157 patients with large B-cell lymphoma were treated in the expansion cohort. The median age was 68 years, and patients had a median of three prior lines of treatment. This was a heavily pretreated patient population with 39% of patients having received a prior CAR-T and 83% refractory to the last line of treatment. The overall response rate in the study was 59% with 41% experiencing a complete response. A median follow-up time of 31 months. The median duration of CR has not yet been reached. An estimated 54% of complete responders remained in CR at 30 months. In patients in complete response, 80% of patients achieved MRD negativity at cycle 3 and 92% of patients experienced MRD negativity at any time point as assessed by clonoSEQ MRD. The most common treatment emergent adverse events were cytokine release syndrome, occurring at 51% of patients, fatigue, fever, neutropenia, diarrhea, nausea, anemia, and infections. There were 29% of patients that had a grade three or higher serious infection, and 10% discontinued therapy due to infection. As this trial was conducted during the COVID-19 pandemic and the omicron variant, there were 32 cases of COVID and nine deaths due to COVID. In the optimization cohort, the uniform use of dexamethasone and hydration, the incidents and severity of CRS occurred in about 37% of patients, and with the majority being low grade. Most CRS occurred after the first full dose of treatment and CRS events all resolved. Hospitalization was not mandatory and was at the discretion of the investigator. 60% of patients received outpatient therapy and only one patient required subsequent inpatient admission. After outpatient treatment, the remaining CRS events were managed without hospitalization. In summary, with over 2.5 years of follow-up of single agent Epcoritamab in relapse refractory large cell lymphoma, including high risk patient populations with prior CAR-T and primary refractory disease, the data continues to show ongoing durable responses in patients who achieve a CR and 62% of patients remain in CR at two years. In the optimization cohort data, in addition to another abstract printed in ash with outpatient Epcoritamab lends support to the safety of fully outpatient administration.

Related Videos

Skin Cancer

Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial

Christian U. Blank, MD, PhD, of the Netherlands Cancer Institute, discusses findings of an investigator-initiated phase III trial showing that neoadjuvant ipilimumab plus nivolumab followed by response-driven adjuvant treatment improved event-free survival in patients with macroscopic, resectable stage III melanoma compared with adjuvant nivolumab (LBA2)

Pancreatic Cancer

Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy

Belinda Lee, MBBS, of Peter MacCallum Cancer Centre, Northern Health, Walter & Eliza Hall Institute, Melbourne, discusses findings from the AGITG DYNAMIC-Pancreas trial on the potential role of serial circulating tumor DNA testing after upfront surgery to guide adjuvant chemotherapy for early-stage disease (Abstract 107).

Breast Cancer

Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy

Reshma Jagsi, MD, DPhil, of Emory University Winship Cancer Institute, and Tarah J. Ballinger, MD, of Indiana University Simon Comprehensive Cancer Center, discuss the disparate burden of taxane-induced peripheral neuropathy in Black women with early-stage breast cancer and how a tailored trial for this population showed that using docetaxel as the preferred taxane may be beneficial (LBA503).

Gynecologic Cancers

Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab

Don S. Dizon, MD, of Legorreta Cancer Center at Brown University and Lifespan Cancer Institute, discusses final phase II results of the BrUOG 354 trial showing that, for patients with ovarian and other extrarenal clear cell cancers, nivolumab and ipilimumab warrant further evaluation against standard treatment, given the historically chemotherapy-resistant nature of the disease (LBA5500).

Prostate Cancer

Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, and Samuel R. Denmeade, MD, of Johns Hopkins University School of Medicine, discuss a study showing that patients with metastatic castration-resistant prostate whose disease is progressing on abiraterone with androgen-receptor alterations detected in the blood may benefit from bipolar androgen therapy. Routine liquid biopsy testing may enable further adoption of bipolar treatment (Abstract 5003).

Advertisement

Advertisement




Advertisement